CA2030345A1 - Utilisation d'un compose de 15-ceto-prostaglandines pour l'amelioration des fonctions encephaliques - Google Patents

Utilisation d'un compose de 15-ceto-prostaglandines pour l'amelioration des fonctions encephaliques

Info

Publication number
CA2030345A1
CA2030345A1 CA2030345A CA2030345A CA2030345A1 CA 2030345 A1 CA2030345 A1 CA 2030345A1 CA 2030345 A CA2030345 A CA 2030345A CA 2030345 A CA2030345 A CA 2030345A CA 2030345 A1 CA2030345 A1 CA 2030345A1
Authority
CA
Canada
Prior art keywords
keto
improvement
prostaglandin compound
encephalic
function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2030345A
Other languages
English (en)
Other versions
CA2030345C (fr
Inventor
Ryuji Ueno
Hiroyoshi Osama
Tomio Oda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Ueno Seiyaku Oyo Kenkyujo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP8543990A external-priority patent/JPH07116135B2/ja
Application filed by Ueno Seiyaku Oyo Kenkyujo KK filed Critical Ueno Seiyaku Oyo Kenkyujo KK
Publication of CA2030345A1 publication Critical patent/CA2030345A1/fr
Application granted granted Critical
Publication of CA2030345C publication Critical patent/CA2030345C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002030345A 1989-11-22 1990-11-20 Utilisation d'un compose de 15-ceto-prostaglandines pour l'amelioration des fonctions encephaliques Expired - Lifetime CA2030345C (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP303839/1989 1989-11-22
JP30383989 1989-11-22
JP7611/1990 1990-01-17
JP761190 1990-01-17
JP8543990A JPH07116135B2 (ja) 1990-03-30 1990-03-30 ６，１５―ジケト―５―ハロプロスタグランジンｅ類
JP85439/1990 1990-03-30

Publications (2)

Publication Number Publication Date
CA2030345A1 true CA2030345A1 (fr) 1991-05-23
CA2030345C CA2030345C (fr) 1998-12-08

Family

ID=27277677

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002030345A Expired - Lifetime CA2030345C (fr) 1989-11-22 1990-11-20 Utilisation d'un compose de 15-ceto-prostaglandines pour l'amelioration des fonctions encephaliques

Country Status (9)

Country Link
US (3) US5117042A (fr)
EP (1) EP0435443B1 (fr)
KR (2) KR0147057B1 (fr)
AT (1) ATE141793T1 (fr)
CA (1) CA2030345C (fr)
DE (1) DE69028289T2 (fr)
DK (1) DK0435443T3 (fr)
ES (1) ES2093636T3 (fr)
GR (1) GR3020902T3 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG55008A1 (en) * 1993-02-03 1998-12-21 Teijin Ltd Pharmaceutical composition for the therapy of cerebral thrombosis
HU223345B1 (hu) 1995-12-20 2004-08-30 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Eljárás alfa, béta-telítetlen ketonok sztereoszelektív redukciójára
KR19990036322A (ko) * 1996-06-10 1999-05-25 류지 우에노 엔도텔린길항제
US6680339B2 (en) 1996-11-12 2004-01-20 Alcon Manufacturing, Ltd. 15-fluoro prostaglandins as ocular hypotensives
ATE202557T1 (de) 1996-11-12 2001-07-15 Alcon Lab Inc 15-fluoro-prostaglandine als augendrucksenkende mittel
ATE227266T1 (de) * 1997-09-09 2002-11-15 Procter & Gamble Aromatische c16-c20-substituierte tetrahydro- prostaglandine und ihre verwendung als prostaglandin f agonisten
WO1999012895A1 (fr) * 1997-09-09 1999-03-18 The Procter & Gamble Company Prostaglandines aromatiques tetrahydro substituees par c16-c20 utilisees comme agonistes fp
DK0978284T3 (da) * 1997-11-28 2008-10-27 Sucampo Ag Anvendelse af 15-keto-prostaglandin-E-forbindelser som endothelinantagonister
HUP0200258A2 (hu) 1999-03-05 2002-05-29 The Procter & Gamble Co. C16-telítetlen FP-szelektív prosztaglandin analógok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DE60010913T2 (de) * 1999-10-15 2005-06-09 Sucampo Ag Bizyklische Verbindungen, Zusammenstellung und Verfahren zu ihrer Stabilisierung
AU2001239551B8 (en) 2000-03-24 2005-11-24 Sucampo Ag Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
TWI384988B (zh) * 2005-01-27 2013-02-11 Sucampo Ag 處理中樞神經系統失常用之組成物
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US9382272B2 (en) 2009-01-22 2016-07-05 Apotex Pharmachem Inc. Methods of making lubiprostone and intermediates thereof
WO2013022079A1 (fr) 2011-08-05 2013-02-14 Sucampo Ag Procédé de traitement de la schizophrénie
CN104140410B (zh) * 2013-05-09 2017-12-15 江苏豪森药业集团有限公司 鲁比前列酮的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0153858A3 (fr) * 1984-02-29 1985-12-11 The Upjohn Company Application thérapeutique de prostaglandines
JPS62198616A (ja) * 1986-02-24 1987-09-02 Res Dev Corp Of Japan 脳血流量改善・脳細胞保護剤
CA1322749C (fr) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandines de la serie d, et tranquilisants et soporifiques en contenant
CA1323364C (fr) * 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandines e et agents anti-ulcereux contenant celles-ci
CA1324129C (fr) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandines de la serie f
DE3869471D1 (de) * 1987-05-15 1992-04-30 Ueno Seiyaku Oyo Kenkyujo Kk Fiebersteigende zusammensetzung.
ES2052735T3 (es) * 1987-09-18 1994-07-16 R Tech Ueno Ltd Un metodo para producir un agente hipotensor ocular.
GB2210556B (en) * 1987-10-02 1991-07-17 Ueno Seiyaku Oyo Kenkyujo Kk The use of 15-keto-16-halo-prostaglandins in cathartic compositions
JP2597649B2 (ja) * 1988-05-11 1997-04-09 株式会社上野製薬応用研究所 気管・気管支拡張剤
AU619543B2 (en) * 1988-05-11 1992-01-30 Sucampo Ag Use of 15-ketoprostaglandin e or f compounds for uterine contraction
EP0343904B1 (fr) * 1988-05-23 1993-04-28 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Composition provoquant l'hypersphyxie
US5106809A (en) * 1990-12-14 1992-04-21 Exxon Research And Engineering Company High activity, high yield tin modified platinum-iridium catalysts, and reforming process utilizing such catalysts

Also Published As

Publication number Publication date
EP0435443A3 (en) 1993-01-27
ATE141793T1 (de) 1996-09-15
US5290811A (en) 1994-03-01
US5426115A (en) 1995-06-20
CA2030345C (fr) 1998-12-08
EP0435443B1 (fr) 1996-08-28
GR3020902T3 (en) 1996-11-30
KR0167745B1 (ko) 1999-01-15
KR910009269A (ko) 1991-06-28
DE69028289D1 (de) 1996-10-02
DE69028289T2 (de) 1997-01-09
EP0435443A2 (fr) 1991-07-03
ES2093636T3 (es) 1997-01-01
DK0435443T3 (da) 1996-09-16
US5117042A (en) 1992-05-26
KR0147057B1 (ko) 1998-08-17

Similar Documents

Publication Publication Date Title
CA2030345A1 (fr) Utilisation d'un compose de 15-ceto-prostaglandines pour l'amelioration des fonctions encephaliques
AU7404791A (en) Treatment of cataract with 15-keto-prostaglandin compounds
DE3865817D1 (fr)
CA2029596A1 (fr) Medicaments contenant de l'acide lipoique r-a
AR244651A1 (es) Procedimiento de fluoracion en fase de gas
DE3779053D1 (fr)
AU2868789A (en) 1,4-disubstituted-piperidinyl compounds
EP0455448A3 (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
AU3392893A (en) Methods for preventing the expression of a protease
PH25605A (en) 16-dehydro-vitamin d3-derivatives, medicament contatining said compounds
GR3019760T3 (en) Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
WO1991001958A3 (fr) 11β-ARYL-GONA-4,9-DIENE-3-ONES
EP0424156A3 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
AU4918790A (en) Medicament
CA2030346A1 (fr) Traitement de troubles cardiaques a l'aide de composes de 15-ceto-prostaglandines
EP0430552A3 (en) Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
AU6704390A (en) 10-(2'-hydroxy-3'-alkoxy-1,4,7-triscarboxymethyl-1,4,7,10- tetraazacyclododecanes
AU639322B2 (en) Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
AU591419B2 (en) Medicament for curing arteriosclerosis comprising pyrimido (2,1-b) benzothiazole derivative
EP0401262A4 (en) 24r-scymnol, and preparation and use thereof
IE902286L (en) Use of isoxazolin-3-one derivatives as antidepressants
GR3022217T3 (en) Treatment of cataract with prostacyclin compounds
AU5889490A (en) Syringes
AU4726289A (en) Oxazolidine compound
AU6813090A (en) Novel compounds of the diterpene type

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry